Astria Therapeutics (ATXS) Competitors $7.27 -0.18 (-2.42%) Closing price 09/24/2025 04:00 PM EasternExtended Trading$7.28 +0.01 (+0.14%) As of 09/24/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATXS vs. AVDL, BHVN, EWTX, ARDX, SDGR, JANX, COGT, GPCR, ABCL, and TLRYShould you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Avadel Pharmaceuticals (AVDL), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Ardelyx (ARDX), Schrodinger (SDGR), Janux Therapeutics (JANX), Cogent Biosciences (COGT), Structure Therapeutics (GPCR), AbCellera Biologics (ABCL), and Tilray Brands (TLRY). These companies are all part of the "pharmaceutical products" industry. Astria Therapeutics vs. Its Competitors Avadel Pharmaceuticals Biohaven Edgewise Therapeutics Ardelyx Schrodinger Janux Therapeutics Cogent Biosciences Structure Therapeutics AbCellera Biologics Tilray Brands Avadel Pharmaceuticals (NASDAQ:AVDL) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk. Does the media refer more to AVDL or ATXS? In the previous week, Astria Therapeutics had 4 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 8 mentions for Astria Therapeutics and 4 mentions for Avadel Pharmaceuticals. Astria Therapeutics' average media sentiment score of 0.81 beat Avadel Pharmaceuticals' score of 0.26 indicating that Astria Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avadel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Astria Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate AVDL or ATXS? Avadel Pharmaceuticals presently has a consensus price target of $20.86, indicating a potential upside of 33.79%. Astria Therapeutics has a consensus price target of $30.20, indicating a potential upside of 315.41%. Given Astria Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Astria Therapeutics is more favorable than Avadel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avadel Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.11Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Which has preferable valuation and earnings, AVDL or ATXS? Avadel Pharmaceuticals has higher revenue and earnings than Astria Therapeutics. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Astria Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvadel Pharmaceuticals$169.12M8.95-$48.83M-$0.03-519.67Astria TherapeuticsN/AN/A-$94.26M-$2.01-3.62 Do institutionals & insiders believe in AVDL or ATXS? 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are owned by institutional investors. 5.2% of Avadel Pharmaceuticals shares are owned by company insiders. Comparatively, 4.5% of Astria Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, AVDL or ATXS? Avadel Pharmaceuticals has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Is AVDL or ATXS more profitable? Astria Therapeutics has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -1.32%. Avadel Pharmaceuticals' return on equity of -3.73% beat Astria Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avadel Pharmaceuticals-1.32% -3.73% -1.73% Astria Therapeutics N/A -56.39%-36.08% SummaryAvadel Pharmaceuticals beats Astria Therapeutics on 8 of the 15 factors compared between the two stocks. Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXS vs. The Competition Export to ExcelMetricAstria TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$420.44M$3.15B$5.77B$10.42BDividend YieldN/A2.36%5.68%4.61%P/E Ratio-3.6220.7676.2826.42Price / SalesN/A444.26552.28127.65Price / CashN/A45.9137.5661.52Price / Book1.839.8313.186.39Net Income-$94.26M-$52.73M$3.29B$271.13M7 Day Performance-2.81%1.84%0.84%0.93%1 Month Performance13.24%7.48%5.03%7.52%1 Year Performance-31.42%19.92%71.27%30.06% Astria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXSAstria Therapeutics3.0825 of 5 stars$7.27-2.4%$30.20+315.4%-41.8%$420.44MN/A-3.6230AVDLAvadel Pharmaceuticals2.642 of 5 stars$16.00-1.2%$20.86+30.4%+22.0%$1.57B$169.12M-533.3370BHVNBiohaven3.1834 of 5 stars$14.92+4.2%$50.07+235.7%-69.4%$1.51BN/A-1.95239EWTXEdgewise Therapeutics2.3282 of 5 stars$15.10+5.9%$40.55+168.5%-36.0%$1.50BN/A-9.7460ARDXArdelyx4.2573 of 5 stars$6.22+0.2%$11.70+88.1%+3.7%$1.50B$333.61M-27.0490SDGRSchrodinger2.8375 of 5 stars$19.72+1.4%$27.83+41.1%+0.8%$1.43B$207.54M-7.95790JANXJanux Therapeutics2.4283 of 5 stars$23.51+0.3%$78.31+233.1%-53.0%$1.41B$10.59M-13.0630COGTCogent Biosciences2.6776 of 5 stars$12.51+4.5%$20.00+59.9%+21.1%$1.36BN/A-7.0380GPCRStructure Therapeutics3.1808 of 5 stars$24.45+3.7%$68.67+180.8%-41.8%$1.36BN/A-23.29136ABCLAbCellera Biologics3.1204 of 5 stars$4.83+7.1%$8.00+65.6%+89.3%$1.35B$28.83M-8.78500TLRYTilray Brands2.8375 of 5 stars$1.20-0.8%$1.94+61.5%-26.7%$1.33B$821.31M-0.522,842 Related Companies and Tools Related Companies Avadel Pharmaceuticals Competitors Biohaven Competitors Edgewise Therapeutics Competitors Ardelyx Competitors Schrodinger Competitors Janux Therapeutics Competitors Cogent Biosciences Competitors Structure Therapeutics Competitors AbCellera Biologics Competitors Tilray Brands Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXS) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATXS Stock Alerts